2 Clarke Drive
Cranbury, NJ 08512
Andrea Casadei Gardini, MD, and Stephen L. Chan, MD, examine the use of TACE and TARE-Y90 for the treatment of HCC.
Josep M. Llovet, MD, PhD: We assume that the primary treatment for this patient is resection, but some centers might consider transarterial radioembolization Y-90 or even TACE [transarterial chemoembolization]. What’s your opinion about these treatments at this early stage?
Andrea Casadei Gardini, MD: This patient has a very high risk of relapse after surgery, and neoadjuvant treatment is a good option for our patient. Between days on radioembolization, I prefer radioembolization because the lesion of our patient is often 7 cm and their response is 2 days, and this isn’t better. It’s important to offer neoadjuvant treatment. We select patients with response and the probability of a better genetic profile. It’s important to perform neoadjuvant therapy for this patient before surgery. We don’t have phase 3 trial data, but we’re moving on with neoadjuvant therapy and locoregional therapy before surgery.
Transcript Edited for Clarity